Pactiv Evergreen announces antitrust approval for Novolex acquisition at $18.00 per share, closing expected in Q2 2025.
Quiver AI Summary
Pactiv Evergreen Inc. has announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired, allowing for its planned acquisition by Novolex® at a price of $18.00 per share in cash. The transaction is expected to finalize in the second quarter of 2025, subject to foreign antitrust approvals and other standard closing conditions. Following the deal's completion, Pactiv Evergreen will transition to being a privately held company with its stock delisted from Nasdaq. Goldman Sachs & Co. and Lazard Frères are financial advisors for the transaction, with Paul Hastings LLP serving as legal advisor. The release also includes forward-looking statements and cautions regarding potential risks and uncertainties associated with the completion of the acquisition.
Potential Positives
- Expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act indicates progress towards the completion of the acquisition by Novolex, enhancing shareholder confidence.
- The proposed acquisition at $18.00 per share in cash represents a significant liquidity event for shareholders and confirms the company's value in the market.
- The completion of the transaction will allow Pactiv Evergreen to operate as a privately held company, potentially enabling more strategic flexibility and focus without public market pressures.
Potential Negatives
- The transition to becoming a privately held company could lead to reduced transparency for shareholders and potential concerns regarding governance and operational oversight.
- Significant uncertainties are addressed in the press release regarding the completion of the acquisition, including risks of litigation and disruptions that may adversely affect Pactiv Evergreen’s business operations during the transaction.
- The possibility of significant stock price decline if the acquisition is not completed raises concerns for investors regarding the stability of their investments in the company.
FAQ
What is the recent acquisition announcement for Pactiv Evergreen?
Pactiv Evergreen announced its acquisition by Novolex® for $18.00 per share in cash, with closing expected in Q2 2025.
What does the Hart-Scott-Rodino Act pertain to?
The Hart-Scott-Rodino Antitrust Improvements Act requires companies to notify the government about mergers and acquisitions to prevent antitrust issues.
What will happen to Pactiv Evergreen after the acquisition?
After the acquisition, Pactiv Evergreen will become a privately held company and its stock will no longer trade on Nasdaq.
Who are the advisors for this transaction?
Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC are the financial advisors; Paul Hastings LLP is the legal advisor to Pactiv Evergreen.
Where can more information about the transaction be found?
Shareholders can find relevant documents on the SEC's website or on Pactiv Evergreen's investor relations page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PTVE Hedge Fund Activity
We have seen 60 institutional investors add shares of $PTVE stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. added 2,317,658 shares (+5350.1%) to their portfolio in Q3 2024, for an estimated $26,676,243
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,714,956 shares (+63.7%) to their portfolio in Q3 2024, for an estimated $19,739,143
- AMERICAN CENTURY COMPANIES INC removed 768,790 shares (-19.7%) from their portfolio in Q3 2024, for an estimated $8,848,772
- FIRST TRUST ADVISORS LP added 601,477 shares (+590.9%) to their portfolio in Q3 2024, for an estimated $6,923,000
- SEGALL BRYANT & HAMILL, LLC added 338,776 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,899,311
- DIMENSIONAL FUND ADVISORS LP added 303,940 shares (+12.8%) to their portfolio in Q3 2024, for an estimated $3,498,349
- ADVISORS ASSET MANAGEMENT, INC. removed 274,471 shares (-44.3%) from their portfolio in Q3 2024, for an estimated $3,159,161
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LAKE FOREST, Ill., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) (NASDAQ: PTVE) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company’s previously announced definitive agreement to be acquired by Novolex® for $18.00 per share in cash.
The transaction is expected to close in the second quarter of 2025, subject to receipt of foreign antitrust approvals and satisfaction of other customary closing conditions. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq.
Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC are acting as financial advisors and Paul Hastings LLP is acting as legal advisor to Pactiv Evergreen.
About Pactiv Evergreen
Pactiv Evergreen is a leading manufacturer and distributor of fresh foodservice and food merchandizing products and fresh beverage cartons in North America. Pactiv Evergreen produces a broad range of on-trend and feature-rich products that protect, package and display food and beverages for today’s consumers. Its products, many of which are made with recycled, recyclable or renewable materials, are sold to a diversified mix of customers, including restaurants, foodservice distributors, retailers, food and beverage producers, packers and processors. Learn more at www.pactivevergreen.com.
Note to Investors Regarding Forward-Looking Statements
This press release contains forward-looking statements that reflect Pactiv Evergreen’s current views with respect to certain current and future events. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding the expected timing of closing of the proposed transaction. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “likely” or “continue,” the negative of these terms and other comparable terminology. These statements are only predictions based on Pactiv Evergreen’s expectations and projections about future events as of the date of this press release and are subject to a number of risks, uncertainties and assumptions that may prove incorrect, any of which could cause actual results to differ materially from those expressed or implied by such statements, including, among others, (i) the completion of the proposed transaction on the anticipated terms and timing, including obtaining foreign antitrust approvals, and the satisfaction of other conditions to the completion of the proposed transaction; (ii) potential litigation relating to the proposed transaction that could be instituted against Pactiv Evergreen or its directors, managers or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the proposed transaction (including the ability of certain counterparties to terminate or amend contracts upon a change of control) will harm Pactiv Evergreen’s business, including current plans and operations, including during the pendency of the proposed transaction; (iv) the ability of Pactiv Evergreen to retain and hire key personnel; (v) the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction and integration matters; (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (vii) legislative, regulatory and economic developments; (viii) potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Pactiv Evergreen’s financial performance; (ix) certain restrictions during the pendency of the proposed transaction that may impact Pactiv Evergreen’s ability to pursue certain business opportunities or strategic transactions; (x) the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xi) the ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the proposed transaction; (xii) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction; (xiii) the risk that Pactiv Evergreen’s stock price may decline significantly if the proposed transaction is not consummated; and (xiv) those risks described under the heading “Risk Factors” in Pactiv Evergreen’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission, or SEC, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024 filed with the SEC. New risks emerge from time to time, and it is not possible for Pactiv Evergreen to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement that Pactiv Evergreen makes. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as otherwise required by law, Pactiv Evergreen undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional Information and Where to Find It
Pactiv Evergreen has filed a definitive information statement on Schedule 14C for its shareholders with respect to the approval of the proposed transaction and may file or furnish other documents with the SEC regarding the same. This press release is not a substitute for the information statement on Schedule 14C or any other document that Pactiv Evergreen may file with the SEC or send to its shareholders in connection with the proposed transaction. You may obtain copies of all documents filed by Pactiv Evergreen with the SEC regarding this transaction, free of charge, at the SEC’s website, www.sec.gov or from Pactiv Evergreen’s website at https://investors.pactivevergreen.com/financial-information/sec-filings.
Shareholders of Pactiv Evergreen are urged to carefully read all relevant documents filed with the SEC, including the information statement on Schedule 14C, as well as any amendments or supplements to these documents, because they contain important information about the proposed transaction.
Contacts
Investors:
Curt Worthington
Vice President, Strategy & Investor Relations
[email protected]
Media:
Beth Kelly
Sr. Director, Communications
[email protected]
Andi Rose / Ed Trissel / Tim Ragones
Joele Frank, Wilkinson Brimmer Katcher
[email protected]